Allergy

Autoimmune Diseases

Biosimilars

COVID-19

Cannabidiol (CBD)

Cardiology

Compounding

Continuous Glucose Monitoring

Dermatology

Diabetes

Digestive Health

Endocrinology

Eye Health

Generics

Headache and Migraine

Immunization

Infectious Disease

Influenza

Medical Devices

Mental and Behavioral Health

Neurology

Obesity Management

Oncology

Nonopioid Pain Management

Pain Management

Pediatrics

Public Health

Rare Diseases

Respiratory

Rheumatology

Shingles

Substance Use Disorder

Technology and Data

Veterinary Pharmacy 

Women's Health

News

FDA Updates

Law and Advocacy

Technology Trends

Viewpoints

All News

Media

Around the Practice

In-Depth Insights

K-Casts

Script-Ed

Expert Interviews

Podcasts

Conferences

Conference Coverage

Conference Listing

Resources

Disease Awareness 

White Board Video

American Pharmacists Month

CME/CE

Partners

Publications

Drug Topics Journal

Total Pharmacy Journal

Events

Virtual Events

Total Pharmacy Solutions Summit

Business

Business Strategies

Patient Services

Pharmacy Inventory

Law and Regulations

All Business News

Practice Type

Independent Pharmacy

Chain Pharmacy

Specialty Pharmacy

Health System Pharmacy

Pharmacy Technicians

Subscribe

Articles

Researchers explored the benefits of tai chi and prevalence of liver disease in patients with osteoarthritis.

Tai Chi Intervention, Liver Disease Prevalence for People with OA | ACR Convergence

Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.

Sotagliflozin’s Effect on BP Remains in T2D Regardless of Kidney Function | AHA 2024

“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.

Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024

Lauren Biscaldi is the Managing Editor of Drug Topics. 

The Mediterranean diet is largely considered one of the healthiest diets. 

Despite Benefits, Mediterranean Diet Adherence in RA Remains Low | ACR Convergence

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Drug Topics

Facebook

LinkedIn

Spotlight

NCPA Annual Convention

1rem

Authors

Derek Borkowski is a first-year PharmD student at the University of Minnesota College of Pharmacy, Duluth. Contact him at borko028@d.umn.edu.

A pharmacy student shares his first semester.

Pharmacy education shifts the paradigm

journal explores issues within pharmacy, from the impact advocacy can have in community pharmacies to staffing shortages across multiple sectors within pharmacy. This month’s issue also explored the importance of disease awareness months and how they are opportunities to maximize valued care. Check out a preview of this month’s issue here.

download the PDF of the Total Pharmacy August 2024 issue here

Don’t get left behind: Sign up today for our 

 and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.

See what’s trending in pharmacy with a preview of the Total Pharmacy August issue.

Total Pharmacy

In This Issue: Total Pharmacy August 2024

Combining sodium glucose co-transporter 2 inhibitors (SGLT2is) with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer additional protection against cardiovascular and kidney disease in patients with type 2 diabetes (T2D), according to the results of a new meta-analysis published in 

 and presented at the 61st European Renal Association Congress in Stockholm, Sweden.

Separately, SGLT2is and GLP-1RAs have demonstrated cardiovascular benefits. However, little clinical literature has focused on outcomes associated with using the medicines together. Due to the growing prevalence of GLP-1RAs in the 

 and obesity landscape, accelerated by an increasing number of indications for the agent class, this is a crucial area for further study.

The SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C) is the largest assessment of outcomes for the combined therapeutic use of SGLT2is and GLP-1RAs. The study gathered data from 12 large-scale, placebo-controlled trials of SGLT2is involving 73,238 patients with diabetes. Of these, 3065 were already receiving GLP-1RAs.

Overall, SGLT2is lowered the risk of major adverse cardiovascular events by 11% and hospitalization for heart failure or cardiovascular death by 23% compared to placebo. Notably, this benefit was seen regardless of whether patients were also taking GLP-1RAs.

When used together with GLP-1RAs, SGLT2is reduced the risk of chronic kidney disease progression by 33% and slowed the annual loss of kidney function by nearly 60%.

The study found no additional safety concerns when SGLT2is were used in combination with GLP-1RAs.

Study Reveals Robust Benefits of Semaglutide in Protecting Against Kidney, CV Events in Patients With T2D

Current meta-analysis results build off positive results of the landmark FLOW trial (

). Published earlier in May, results of the international, double-blind, randomized, placebo-controlled phase 3 trial spotlighted semaglutide’s effectiveness in lowering the risk of kidney failure, decelerating worsening kidney function, and protecting against the risk of cardiovascular events and death, in patients with T2D.

“SGLT2 inhibitors have clear protective effects against heart failure and chronic kidney disease, while GLP-1 receptor agonists can reduce the risk of heart attack, stroke, and also kidney disease—as recently demonstrated in the landmark FLOW trial,” said Brendon Neuen, lead author, clinical associate professor, senior research fellow at The George Institute for Global Health, and director of kidney trials at Sydney’s Royal North Shore Hospital, in a news release.

 “Our findings support using this combination to further improve outcomes in patients with type 2 diabetes who meet guideline recommendations for both therapies.”

Elevated glucose from diabetes can damage blood vessels in the heart and kidneys, increasing the risk of 

 and kidney disease. In fact, diabetes is the most common cause of chronic kidney disease.

Moreover, estimates predicting that T2D prevalence will more than double in the next 30 years, surpassing 1 billion global cases by 2050, further strengthen the need for research into diabetes care.

 According to Neuen in an interview with 

 conducted over email, the current study offers valuable insights for developing global treatment strategies for the condition.

"These findings, which represent the largest and most comprehensive evaluation of the combined use of SGLT2i and GLP-1RA, provides the clearest evidence yet that combined use of both medicines can further reduce cardiovascular and kidney disease," said Neuen. "We anticipate that these findings will inform how people with diabetes are treated worldwide, including influencing major clinical practice guidelines.

Although current results suggest that using SGLT2is and GLP-1RAs in tandem may offer robust protection against cardiovascular and kidney disease, further research is needed to fully understand the long-term effects of the combination therapy.

Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our 

 and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

1. Apperloo E, Neuen BL et al. Efficacy and safety of sodium glucose co-transporter 2 inhibitors with and without glucagon-like peptide-1 receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled trials. 

. 2024. doi: 10.1016/S2213-8587(24)00183-9

2. Massaro L. Study reveals robust benefits of semaglutide in protecting against kidney, CV events in patients with T2D. 

https://www.drugtopics.com/view/study-reveals-robust-benefits-of-semaglutide-in-protecting-against-kidney-cv-events-in-patients-with-t2d

3. Combining popular diabetes drugs offers complementary heart and kidney benefits. News release. The George Institute for Global Health. July 9, 2024. Accessed July 10, 2024. 

https://www.georgeinstitute.org/media-releases/combining-popular-diabetes-drugs-offers-complementary-heart-and-kidney-benefits

4. Mayo Clinic Staff. Chronic kidney disease. Fact sheet. Accessed July 8, 2024. 

https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521

5. Klein HE. Diabetes prevalence expected to double globally by 2050. 

https://www.ajmc.com/view/diabetes-prevalence-expected-to-double-globally-by-2050

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Clinical

SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease

TaQuina Warren, PharmD: Part 1

TaQuina Warren, PharmD: Part 2

TaQuina Warren, PharmD: Part 3

TaQuina Warren, PharmD, is an independent pharmacist and owner of Focus Pharmacy in Smyrna, Delaware. She has been a community pharmacy owner since 2019 and is touted in high regard amongst community members and peers within the state of Delaware. She prides herself on being a pillar of valued care in her community, and she sat down to discuss her experience in pharmacy.

Warren has always wanted to serve her communities and take care of the people who make those communities thrive. She first wanted to pursue a career as an OBGYN but was later encouraged to consider a profession in pharmacy, and she hasn’t looked back since.

Known as “Dr. Tee” to her patients, Warren has become somewhat of a celebrity in her community. Appearing on programs like “Good Morning America” and being recognized by pharmacy customers on a daily basis, she has garnered a reputation for providing care and always being a resource for the patients within her community.

, Warren discussed her experience as a pharmacist and their expanding role within health care, and she touched on some of the inner workings of her pharmacy practice.

Our coverage of American Pharmacists Month continues all October. To view all of our interviews, 

visit our American Pharmacists Month landing resource center

In an interview with Drug Topics, TaQuina Warren, PharmD, discussed what it means to serve her community and how she has garnered a reputation within her profession.

The Celebrity Pharmacist Bridging Gaps in Community Care

Benjamin Jolley, PharmD: Part 1

Benjamin Jolley, PharmD: Part 2

Benjamin Jolley, PharmD: Part 3

Benjamin Jolley, PharmD, is an independent pharmacist at Jolley’s Compounding Pharmacy in Salt Lake City, Utah. With nearly 20 years in the profession, Jolley shared his insights on the industry as a whole and what his pharmacy experience has been like.

Jolley grew up around the pharmacy profession: His grandfather was a pharmacist, which encouraged Jolley to follow that same career. His entire career has been in independent community pharmacies and he has since evolved into consulting within the independent space.

analysis of pharmacy locations across the country

, detailing the 2000-plus stores that have closed in 2024 alone. And amidst ongoing pressure toward pharmacy benefit manager (PBM) reform, Jolley has teamed up with independents across the country to fight back as an advocate for community pharmacies.

, Jolley discussed his experience as a pharmacist and their expanding role within health care, and he touched on some of the inner workings of his pharmacy practice.

Our coverage of American Pharmacists Month continues all October. To view all of our interviews, 

Drug Topics sat down with Benjamin Jolley, PharmD, of Jolley’s Compounding Pharmacy, to discuss the pharmacy industry and his experience in a myriad of roles within the profession.

An Independent Pharmacist’s Journey to Championing Community Care

Walmart has filed suit against the United States Department of Justice (DOJ) and the Drug Enforcement Administration (DEA), asking a US District Court judge to clarify the roles and responsibilities of pharmacists and pharmacies under the Controlled Substances Act (CSA), the retailer said in a news release.

Although Walmart’s pharmacies have blocked “thousands” of questionable physicians from having their opioids scripts filled by its pharmacists, “certain DOJ officials have long seemed more focused on chasing headlines than fixing the crisis,” the retailer said. “They are now threatening a completely unjustified lawsuit against Walmart, claiming in hindsight pharmacists should have refused to fill otherwise valid opioid prescriptions that were written by the very doctors that the federal government still approves to write prescriptions.”

Walmart is the third-largest pharmacy retailer in the US, with more than 5000 pharmacies nationwide. The supermarket chain has expressed its commitment to fighting the opioid epidemic, which has worsened over the years; overdose deaths from opioids were 4 times higher in 2018 than in 1999.

However, there is no federal law requiring pharmacists to interfere in the phyisician-patient relationship to the degree that DOJ is demanding, according to Walmart. “In fact, expert federal and state health agencies routinely say it is not allowed and potentially harmful to patients with legitimate medical needs,” Walmart said.

On one hand, DOJ is criticizing Walmart for not taking further actions to second-guess opioid presciptions; on the other, state health regulators argue that Walmart is unnecessarily meddling with physician-patient relationships, according to the news release.

“DOJ is forcing Walmart and our pharmacists between a rock and a hard place,” Walmart asserted in its statement.

The confusing dichotomy requires a federal court to clarify the roles and responsibilities of pharmacists and pharmacies, according to Walmart.

“Walmart and our pharmacists are committed to helping address the opioid crisis that has affected so many. We are proud of our pharmacists, who help patients understand the risks about opioid prescriptions, and who have refused to fill hundreds of thousands of opioid prescriptions they thought could be problematic,” Walmart added.

 was filed on October 22 in the US District Court for the Eastern District of Texas.

Walmart sues DOJ and DEA seeking clarity for pharmacists in dispensing prescription opioids. News release. Walmart; October 22, 2020. Accessed October 26, 2020. 

https://corporate.walmart.com/newsroom/2020/10/22/walmart-sues-doj-and-dea-seeking-clarity-for-pharmacists-in-dispensing-prescription-opioids

Redman R. Walmart sues DOJ over pharmacists’ role in dispensing opioid prescriptions. Supermarket News. October 23, 2020. Accessed October 26, 2020. 

https://www.supermarketnews.com/health-wellness/walmart-sues-doj-over-pharmacists-role-dispensing-opioid-prescriptions

Walmart filed a pre-emptive suit against 2 government agencies that are threatening to sue Walmart over its pharmacists filling opioid prescriptions.

Walmart Sues DOJ, DEA to Clarify Pharmacists’ Role in Filling Opioid Prescriptions

Explore how centralized fulfillment can transform your pharmacy operations. This whitepaper details the key benefits of shifting high-volume, repetitive tasks away from individual stores and into a central hub equipped with advanced automation and proprietary software. Learn how this model can improve patient care, enhance medication adherence, and create a better work environment for pharmacists. Discover strategies to address rising prescription volumes and staffing shortages, while reducing operational errors. 

Download this resource now to see how centralized fulfillment can help your pharmacy streamline operations and meet growing patient demands. Request a consultation today to identify the best solution for your organization.

Streamline your pharmacy operations with centralized fulfillment. Discover how automation and advanced software can improve patient care, reduce operational errors, and create a better work environment for pharmacists. Download our whitepaper to learn how centralized fulfillment can address rising prescription volumes and staffing shortages. Request a consultation today to explore the best solution for your pharmacy.

Derek Borkowski, PharmD Candidate 2018

Articles

Latest Updated Articles